CD8A and neoplasm: To validate the enhanced anti-tumor responses of CUL5 KO CD8+ T cells, Cas9/OT-I T cells transduced with the Cul5 sgRNAs or a non-targeting control sgRNA were adoptively transferred into E.G7-OVA tumor-bearing mice subjected to prior sub-lethal irradiation for lymphodepletion63.